Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 113,090
  • Shares Outstanding, K 28,062
  • Annual Sales, $ 0 K
  • Annual Income, $ -46,670 K
  • 60-Month Beta 2.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.58
Trade CRVS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.32
  • Number of Estimates 4
  • High Estimate -0.24
  • Low Estimate -0.41
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +15.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.82 +4.45%
on 11/02/20
4.30 -7.23%
on 11/09/20
+0.03 (+0.76%)
since 10/30/20
3-Month
2.95 +35.25%
on 09/04/20
5.74 -30.49%
on 10/05/20
+0.36 (+9.92%)
since 08/28/20
52-Week
1.01 +295.05%
on 03/16/20
6.88 -42.01%
on 07/07/20
+0.94 (+30.82%)
since 11/29/19

Most Recent Stories

More News
Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exposition

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new data on CPI-818, the Company's ITK inhibitor, will be presented at the 62 American Society...

CRVS : 3.99 (-0.99%)
Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Data to be presented in a poster and an oral session "Hot Topic Symposium: COVID-19 and Cancer" at SITC

CRVS : 3.99 (-0.99%)
Corvus Pharmaceuticals COVID-19 Abstract Selected for "Hot Topic" Oral Session at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its abstract covering updated data from its Phase 1 study investigating the potential for CPI-006...

CRVS : 3.99 (-0.99%)
Corvus: 3Q Earnings Snapshot

BURLINGAME, Calif. (AP) _ Corvus Pharmaceuticals Inc. (CRVS) on Thursday reported a loss of $9.8 million in its third quarter.

CRVS : 3.99 (-0.99%)
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and announced financial results for the third quarter ended September 30, 2020....

CRVS : 3.99 (-0.99%)
Corvus Pharmaceuticals to Present Updated Data from its Clinical Trial of CPI-006 for Patients with COVID-19 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present updated data from its Phase 1 study investigating the potential for CPI-006...

CRVS : 3.99 (-0.99%)
Biotech Stock Roundup: ALXN to Raise Guidance, BMY to Buy MYOK & Other Updates

The biotech sector remains in focus with regulatory, acquisition and other pipeline updates.

ALXN : 122.11 (-1.39%)
REGN : 516.03 (+0.39%)
GILD : 60.67 (+1.07%)
BMY : 62.40 (-1.03%)
MYOK : 224.91 (+0.05%)
CRVS : 3.99 (-0.99%)
BNTX : 124.24 (+12.96%)
Corvus Pharmaceuticals Announces Co-Founding of Angel Pharmaceuticals in China

Angel's pipeline will feature Corvus' three clinical-stage candidates - ciforadenant, CPI-006 and CPI-818 - and its preclinical BTK inhibitor program

CRVS : 3.99 (-0.99%)
New Data from Ciforadenant Phase 1b/2 Clinical Study Presented at ESMO Virtual Congress 2020

Data is part of Genentech's MORPHEUS umbrella program and covers patients with resistant/refractory NSCLC treated with ciforadenant in combination with atezolizumab

CRVS : 3.99 (-0.99%)
Corvus Pharmaceuticals Appoints Edith Mitchell, M.D., to Board of Directors

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Edith P. Mitchell, M.D., has been appointed to the company's Board of Directors. Dr. Mitchell...

CRVS : 3.99 (-0.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible...

See More

Key Turning Points

2nd Resistance Point 4.12
1st Resistance Point 4.06
Last Price 3.99
1st Support Level 3.93
2nd Support Level 3.87

See More

52-Week High 6.88
Fibonacci 61.8% 4.64
Last Price 3.99
Fibonacci 50% 3.95
Fibonacci 38.2% 3.25
52-Week Low 1.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar